TABLE 1.
Study Demographics
| Total Patients Enrolled | Study Total | CD11b | Tmem/Treg |
|---|---|---|---|
| (n = 65) | (n = 31) | (n = 34) | |
| Disease | |||
| UC | 31 (47.69%) | 15 (48.3%) | 16 (47.1%) |
| CD | 34 (52.3%) | 16 (51.6%) | 18 (52.9%) |
| Age at time of collection, y (mean) | 43.81 (18-79) | 45 (18-72) | 42.7% (20-79) |
| Years of disease (mean) | 23.01 (1-65) | 30 (10-61) | 16.2% (1-65) |
| Gender | |||
| Male | 31 (47.6%) | 15 (48.3%) | 16 (47.1%) |
| Female | 34 (52.3%) | 16 (51.6%) | 18 (52.9%) |
| Race | |||
| White | 61 (93.8%) | 29 (93.5%) | 32 (94%) |
| African American | 2 (3%) | 0 (0%) | 2 (5.88%) |
| Asian | 1 (1.5%) | 4 (0%) | 0 (0%) |
| Mixed | 1 (1.5%) | 3 (9.67%) | 0 (0%) |
| Ethnicity | |||
| Not Hispanic | 39 (60%) | 18 (58%) | 21 (61.7%) |
| Hispanic | 26 (40%) | 13 (41.9%) | 13 (38.2%) |
| Jewish | |||
| Yes | 21 (32.3%) | 11 (35%) | 10 (29%) |
| No | 42 (64.6%) | 20 (67.7%) | 22 (64.7%) |
| Unknown | 2 (3%) | 0 (0%) | 2 (5.88%) |
| Medication | |||
| Anti-TNF | 24 (36.9%) | 9 (29%) | 15 (44%) |
| Vedolizumab | 7 (10.76%) | 6 (19.3%) | 1 (2.9%) |
| Ustekinumab | 3 (4.61%) | 4 (12.9%) | 1 (2.9%) |
| Thiopurines | 12 (18.46%) | 2 (6.45%) | 10 (29.4%) |
| Mesalamine | 14 (21.5%) | 8 (25.8%) | 6 (17%) |
| Steroids | 15 (23 %) | 7 (22.5%) | 8 (23.5%) |
| No medications | 10 (15.38%) | 5 (16%) | 5 (14.7%) |
Anti-TNF indicates anti-tumor necrosis factor.